Immune cell therapy for advanced pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new immune cell therapy (EGFRBi armed PBMC) for people with advanced pancreatic cancer that can't be removed by surgery. It aims to see if this treatment can help control the cancer after you've already tried at least one type of chemotherapy and your disease is stable or better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have locally advanced or metastatic pancreatic cancer that can't be cured with standard treatments.
- You've had at least one type of chemotherapy (like gemcitabine or 5FU) and your cancer has been stable or improved for at least 3 months.
- You have cancer that can be measured on scans.
- You are in good general health (able to do daily activities without help) and are 18 or older.
- You are not pregnant, plan to use effective birth control during and for 90 days after treatment, and are not breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new kind of immunotherapy for pancreatic cancer that has not been removed by surgery or has spread. It aims to see if the treatment can help shrink or control the cancer, and you may be eligible whether you have had previous chemotherapy or not.
This trial tests an experimental cell therapy called MT-601 for pancreatic cancer that is advanced. The treatment uses your own immune cells to fight the cancer, and the goal is to see if it is safe and helps people whose cancer is stable or shrinking on chemotherapy.
This trial tests a new treatment using specially engineered immune cells (CAR macrophages) that are designed to find and attack a protein called c-MET on pancreatic cancer cells. It may help people whose cancer has not responded to previous treatments or who could not tolerate them.
This trial tests a new type of immunotherapy (called Lm-LLO-TT) combined with a standard chemotherapy drug (gemcitabine) for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination is safe and effective.
This trial tests a new combination of drugs and radiation for people with pancreatic cancer that has spread. It aims to shrink tumors and improve quality of life by using an immunotherapy drug, two chemotherapies, and precisely targeted radiation.
This trial tests an experimental cell therapy using immune cells called iNKT cells, which are designed to attack pancreatic cancer. It may be an option for people who have already tried standard treatments and are looking for something new.
Hear when a new Pancreas Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.